Short answer
Vertex Pharmaceuticals (VRTX) filed an 8-K current report with the SEC on October 20, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Daniel Brennan appointed director on October 20, 2026, expanding the Board from 10 to 11 members.
Vertex Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Daniel Brennan appointed director on October 20, 2026, expanding the Board from 10 to 11 members
- Audit and Finance Committee addition strengthens financial oversight with former Boston Scientific CFO experience
- $400,000 restricted stock unit award, vesting in October 2027
- No reportable related-party transactions or appointment arrangements disclosed
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vertex Pharmaceuticals 8-K filings
Get the next VRTX 8-K as it lands
Follow VRTX for push alerts, or ask the research agent what this filing means.